{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043665","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2023-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.148202+00:00","generated_at":"2026-06-07T18:05:29.691690+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"bioAffinity appoints Jamie Platt to board; Mohsin Meghji resigns","bullets":["Jamie Platt, Ph.D., appointed to board effective Dec. 1, 2023; also joins Compensation Committee.","Platt brings 20 years of genomics/diagnostics experience; led two M&A exits worth ~$1B combined.","Mohsin Meghji resigned same day for personal reasons, no disagreement with company.","Platt receives standard non-employee director compensation: $25k annual fee + quarterly restricted stock grant valued at $18,750.","She currently serves as CEO of Pictor Ltd. and President/CEO of BRIDGenomics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043665","json":"https://secwatch.observer/filing/0001493152-23-043665.json","markdown":"https://secwatch.observer/filing/0001493152-23-043665.md","text":"https://secwatch.observer/filing/0001493152-23-043665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:05:29.691690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f5db08550","claim":"Mohsin Y. Meghji resigned as Director at bioAffinity Technologies, Inc..","evidence_excerpt":"On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cf08fe23d1","claim":"Jamie Platt was appointed as Director at bioAffinity Technologies, Inc..","evidence_excerpt":"On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223043665/0001493152-23-043665-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}